Home Cart Sign in  
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 878385-84-3 Chemical Structure| 878385-84-3

Structure of AZD-5069
CAS No.: 878385-84-3

Chemical Structure| 878385-84-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

AZD 5069 is a selective and reversible antagonist of CXCR2 that can inhibit CXCL8 binding to CXCR2 with pIC50 of 9.1.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of AZD-5069

CAS No. :878385-84-3
Formula : C18H22F2N4O5S2
M.W : 476.52
SMILES Code : O=S(N1CCC1)(NC2=NC(SCC3=CC=CC(F)=C3F)=NC(O[C@H](C)[C@@H](O)CO)=C2)=O
MDL No. :MFCD19443645
InChI Key :QZECRCLSIGFCIO-RISCZKNCSA-N
Pubchem ID :56645576

Safety of AZD-5069

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H360
Precautionary Statements:P201-P202-P280-P308+P313-P405-P501
Class:6.1
UN#:2811
Packing Group:

Related Pathways of AZD-5069

GPCR

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
PANC-1 tumor spheroids 1 µM 24 h To evaluate the effect of AZD-5069 on PANC-1 tumor spheroid invasion, results showed that AZD-5069 significantly reduced tumor spheroid invasion in the 'contact' scenario Sci Rep. 2024 Jun 19;14(1):14142
dHL-60 cells 1 µM 30 min To evaluate the effect of AZD-5069 on dHL-60 cell migration, results showed that AZD-5069 significantly reduced dHL-60 cell migration toward tumor spheroids Sci Rep. 2024 Jun 19;14(1):14142
bEND3 cells 1 mM 24 h AZD-5069 significantly inhibited EdU uptake of bEND3 cells, indicating that CAMP induces cerebral endothelial cell proliferation by binding to CXCR2 receptor J Cereb Blood Flow Metab. 2023 Sep;43(9):1503-1518

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice Middle cerebral artery occlusion model (MCAO) Intracerebroventricular injection (ICV) 10 mg/kg Single dose AZD-5069 significantly increased infarct volume and aggravated BBB disruption, suggesting that CXCR2 receptor is the major receptor mediating CAMP-induced endothelial cell proliferation after stroke J Cereb Blood Flow Metab. 2023 Sep;43(9):1503-1518
C57BL/6 J male mice High-fat diet-induced insulin resistance and liver pathology model Oral (via high-fat diet formulation) 593.8 mg/4057 kcal 16 weeks To evaluate the effects of AZD5069 on insulin sensitivity and liver pathology under high-fat diet conditions. Results showed that compared to the HFD group, the AZD5069 group exhibited improved insulin sensitivity, a modest reduction in weight gain, and significant improvements in liver pathology and NAFLD/NASH-related markers. Additionally, AZD5069 reduced neutrophil accumulation in the liver. Cardiovasc Diabetol. 2022 Jul 12;21(1):130

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02499328 Advanced Solid Tumors & Metast... More >>atic Squamous Cell Carcinoma of the Head and Neck Less << Phase 1 Phase 2 Recruiting October 31, 2019 -
NCT01962935 Chronic Obstructive Pulmonary ... More >>Disease (COPD). Less << Phase 1 Completed - United Kingdom ... More >> Research Site London, United Kingdom Less <<
NCT01989520 Uncontrolled and Persistent As... More >>thma Less << Phase 1 Completed - United Kingdom ... More >> Research Site London, United Kingdom Less <<
NCT02583477 Metastatic Pancreatic Ductal A... More >>denocarcinoma Less << Phase 1 Phase 2 Completed - United States, New York ... More >> Research Site Rochester, New York, United States, 14642 United Kingdom Research Site Cambridge, United Kingdom, CB2 0QQ Research Site Glasgow, United Kingdom, G12 0YN Research Site London, United Kingdom, SE1 9RY Research Site London, United Kingdom, W12 0NN Research Site Manchester, United Kingdom, M20 4BX Research Site Wirral, United Kingdom, CH63 4JY Less <<
NCT01255592 Bronchiectasis ... More >> Lung Disease Respiratory Diseases Less << Phase 2 Completed - Czech Republic ... More >> Research Site Ostrava, Czech Republic Research Site Prague, Czech Republic Poland Research Site Krakow, Poland Research Site Lodz, Poland Research Site Warszawa, Poland United Kingdom Research Site Hull, East Yorkshire, United Kingdom Research Site Leicester, Leicestershire, United Kingdom Research Site Birmingham, Wstmid, United Kingdom Research Site Belfast, United Kingdom Research Site Bristol, United Kingdom Research Site Cambridge, United Kingdom Research Site London, United Kingdom Research Site Newcastle-upon-tyne, United Kingdom Research Site Salford, United Kingdom Research Site Wolverhampton, United Kingdom Less <<
NCT01233232 - Completed - -
NCT01255592 - Completed - -
NCT01890148 Asthma Phase 1 Completed - Germany ... More >> Research Site Grosshansdorf, Germany Less <<
NCT01233232 Scientific Terminology Chronic... More >> Obstructive Pulmonary Disease (COPD) Laymen Terminology Chronic Bronchitis and Emphysema Less << Phase 2 Completed - Bulgaria ... More >> Research Site Sofia, Bulgaria Germany Research Site Berlin, Germany Research Site GROßHANSDORF, Germany Hungary Research Site Debrecen, Hungary Research Site Pécs, Hungary Research Site Szeged, Hungary Research Site Százhalombatta, Hungary Ukraine Research Site Kyiv, Ukraine Less <<
NCT01890148 - Completed - -
NCT00953888 Healthy Phase 1 Completed - United Kingdom ... More >> Research Site Nottingham, United Kingdom Less <<
NCT01480739 Chemokine Receptor 2 (CXCR2) A... More >>ntagonist Less << Phase 1 Completed - United Kingdom ... More >> London, UK, United Kingdom Less <<
NCT01051505 Healthy Phase 1 Completed - United Kingdom ... More >> Research Site London Bridge, United Kingdom Less <<
NCT01100047 Healthy Phase 1 Completed - United Kingdom ... More >> Research Site Croydon, United Kingdom Less <<
NCT01704495 - Completed - -
NCT01704495 Asthma Phase 2 Completed - -
NCT01332903 Healthy Phase 1 Completed - United Kingdom ... More >> Research Site London, United Kingdom Less <<
NCT03177187 Metastatic Castration Resistan... More >>t Prostate Cancer Less << Phase 1 Phase 2 Not yet recruiting December 2020 -
NCT01735240 Asthma, Pharm... More >>acokinetics, Cmax, Tmax, λz, AUC, Ketoconazole, Metabolite Less << Phase 1 Completed - United Kingdom ... More >> London, United Kingdom Less <<
NCT01083238 Chronic Obstructive Pulmonary ... More >>Disease Less << Phase 1 Completed - United Kingdom ... More >> Research Site London, United Kingdom Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.10mL

0.42mL

0.21mL

10.49mL

2.10mL

1.05mL

20.99mL

4.20mL

2.10mL

References

 

Historical Records

Categories